These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 35801593)

  • 1. Targeting histone demethylases as a potential cancer therapy (Review).
    Diao W; Zheng J; Li Y; Wang J; Xu S
    Int J Oncol; 2022 Sep; 61(3):. PubMed ID: 35801593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role and prospect of lysine-specific demethylases in cancer chemoresistance.
    Song YQ; Yang GJ; Ma DL; Wang W; Leung CH
    Med Res Rev; 2023 Sep; 43(5):1438-1469. PubMed ID: 37012609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing histone demethylase inhibitors in cells: lessons learned.
    Hatch SB; Yapp C; Montenegro RC; Savitsky P; Gamble V; Tumber A; Ruda GF; Bavetsias V; Fedorov O; Atrash B; Raynaud F; Lanigan R; Carmichael L; Tomlin K; Burke R; Westaway SM; Brown JA; Prinjha RK; Martinez ED; Oppermann U; Schofield CJ; Bountra C; Kawamura A; Blagg J; Brennan PE; Rossanese O; Müller S
    Epigenetics Chromatin; 2017; 10():9. PubMed ID: 28265301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent developments in catalysis and inhibition of the Jumonji histone demethylases.
    Sarah L; Fujimori DG
    Curr Opin Struct Biol; 2023 Dec; 83():102707. PubMed ID: 37832177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Examining the impact of gene variants on histone lysine methylation.
    Van Rechem C; Whetstine JR
    Biochim Biophys Acta; 2014 Dec; 1839(12):1463-76. PubMed ID: 24859469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lysine Demethylation in Pathogenesis.
    Cao J; Yan Q
    Adv Exp Med Biol; 2023; 1433():1-14. PubMed ID: 37751133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present).
    He X; Zhang H; Zhang Y; Ye Y; Wang S; Bai R; Xie T; Ye XY
    Eur J Med Chem; 2022 Mar; 231():114143. PubMed ID: 35101649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting histone lysine methylation in cancer.
    McGrath J; Trojer P
    Pharmacol Ther; 2015 Jun; 150():1-22. PubMed ID: 25578037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of JmjC-domain-containing histone demethylase (KDM2-7) inhibitors for cancer therapy.
    Zhang L; Chen Y; Li Z; Lin C; Zhang T; Wang G
    Drug Discov Today; 2023 May; 28(5):103519. PubMed ID: 36754142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deferiprone: Pan-selective Histone Lysine Demethylase Inhibition Activity and Structure Activity Relationship Study.
    Khodaverdian V; Tapadar S; MacDonald IA; Xu Y; Ho PY; Bridges A; Rajpurohit P; Sanghani BA; Fan Y; Thangaraju M; Hathaway NA; Oyelere AK
    Sci Rep; 2019 Mar; 9(1):4802. PubMed ID: 30886160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15.
    Duan L; Perez RE; Calhoun S; Maki CG
    Cancer Biol Ther; 2022 Dec; 23(1):65-75. PubMed ID: 35100078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taking Me away: the function of phosphorylation on histone lysine demethylases.
    Karakatsanis NM; Hamey JJ; Wilkins MR
    Trends Biochem Sci; 2024 Mar; 49(3):257-276. PubMed ID: 38233282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emerging role of histone lysine demethylases in prostate cancer.
    Crea F; Sun L; Mai A; Chiang YT; Farrar WL; Danesi R; Helgason CD
    Mol Cancer; 2012 Aug; 11():52. PubMed ID: 22867098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Emerging Significance of Histone Lysine Demethylases as Prognostic Markers and Therapeutic Targets in Head and Neck Cancers.
    Dorna D; Paluszczak J
    Cells; 2022 Mar; 11(6):. PubMed ID: 35326475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of histone H3 lysine demethylases in glioblastoma.
    Young D; Guha C; Sidoli S
    Cancer Metastasis Rev; 2023 Jun; 42(2):445-454. PubMed ID: 37286866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular basis for substrate recognition by lysine methyltransferases and demethylases.
    Del Rizzo PA; Trievel RC
    Biochim Biophys Acta; 2014 Dec; 1839(12):1404-15. PubMed ID: 24946978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JIB-04, a Pan-Inhibitor of Histone Demethylases, Targets Histone-Lysine-Demethylase-Dependent AKT Pathway, Leading to Cell Cycle Arrest and Inhibition of Cancer Stem-Like Cell Properties in Hepatocellular Carcinoma Cells.
    Lee J; Kim JS; Cho HI; Jo SR; Jang YK
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A scintillation proximity assay for histone demethylases.
    Yu W; Eram MS; Hajian T; Szykowska A; Burgess-Brown N; Vedadi M; Brown PJ
    Anal Biochem; 2014 Oct; 463():54-60. PubMed ID: 25010373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging of lysine demethylases (KDMs): From pathophysiological insights to novel therapeutic opportunities.
    Arifuzzaman S; Khatun MR; Khatun R
    Biomed Pharmacother; 2020 Sep; 129():110392. PubMed ID: 32574968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting histone lysine demethylases - progress, challenges, and the future.
    Thinnes CC; England KS; Kawamura A; Chowdhury R; Schofield CJ; Hopkinson RJ
    Biochim Biophys Acta; 2014 Dec; 1839(12):1416-32. PubMed ID: 24859458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.